Association between tumor mutational burden (TMB) and mutational profile and its effect on overall survival: A post hoc analysis of patients with TMB-high and TMB-low metastatic cancer treated with immune checkpoint inhibitors (ICI)

被引：0
|
作者：
Xavier, Camila Braganca
Guardia, Gabriela
Lopes, Carlos Diego Holanda
Awni, Beatriz Mendes
Campos, Eduardo Felicio
Alves, Joao Pedro
Camargo, Anamaria Aranha
Galante, Pedro Alexandre Favoretto
Jardim, Denis L.
机构：
[1] Hosp Sirio Libanes, Sao Paulo, Brazil
[2] Falconi Consultants Results, Sao Paulo, Brazil
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2632
引用
收藏
页数：1
相关论文
共 44 条
  • [21] TUMORS WITH HIGHER HETEROGENEITY WERE ASSOCIATED WITH SUPERIOR SURVIVAL OUTCOME AMONGST STAGE I LUNG CANCER PATIENTS WITH LOW TUMOR MUTATIONAL BURDEN (TMB)
    Fridland, Stanislav
    Chae, Young Kwang
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A79 - A79
  • [22] Somatic Alterations and Tumor Mutational Burden (TMB) in Patients with Metastatic Colorectal Cancer (mCRC) Treated with FOLFiRI Plus Bevacizumab or Cetuximab (Fire-3 Trial)
    Stahler, Arndt
    Stintzing, Sebastian
    von Einem, Jobst C.
    Westphalen, C. Benedikt
    Kraemer, Nicole
    Michl, Marlies
    Modest, Dominik Paul
    von Weikersthal, Ludwig Fischer
    Decker, Thomas
    Kiani, Alexander
    Heintges, Tobias
    Kahl, Christoph
    Kullmann, Frank
    Scheithauer, Werner
    Moehler, Markus
    Vehling-Kaiser, Ursula
    Kirchner, Thomas
    Jung, Andreas
    Heinemann, Volker
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 48 - 48
  • [23] Comparative molecular analysis between microsatellite instability-high (MSI-H) tumors with high tumor mutational burden (TMB-H) versus MSI-H tumors with TMB-intermediate/low
    Salem, M. E.
    Puccini, A.
    Grothey, A.
    Xiu, J.
    Goldberg, R.
    Kim, E. S.
    Korn, W. M.
    Lenz, H-J.
    Raghavan, D.
    Marshall, J. L.
    Hall, M. J.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [24] The Predictive Efficacy of Tumor Mutation Burden (TMB) on Nonsmall Cell Lung Cancer Treated by Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
    Zhang Nan
    Wang Guoqing
    Yu Xiaoxu
    Mi Yin
    He Xin
    Li Xue
    Wang Rong
    [J]. BIOMED RESEARCH INTERNATIONAL, 2021, 2021
  • [25] Whole exome sequencing (WES) of non-small cell lung cancer (NSCLC) for tumor mutational burden (TMB) analysis and long-term benefit to immune checkpoint inhibitors (ICIs).
    Felip, Enriqueta
    Navarro, Alejandro
    Callejo, Ana
    Martinez Marti, Alex
    Cedres, Susana
    Pardo, Nuria
    Ros, Javier
    David Assaf, Juan
    Pedrola, Anna
    Viaplana, Cristina
    Sansano, Irene
    Jimenez, Jose
    Nuciforo, Paolo
    Sanso, Miriam
    Dienstmann, Rodrigo
    Amat, Ramon
    Mancuso, Francesco M.
    Vivancos, Ana
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] Stimulator of interferon gene (STING) expression as a biomarker for overall survival in PDL1-negative, TMB-low non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs)
    Hadfield, Matthew James
    Gandhi, Nishant
    Farrell, Alex Patrick
    Azzoli, Christopher G.
    Vanderwalde, Ari M.
    Halmos, Balazs
    Liu, Stephen V.
    El-Deiry, Wafik S.
    Naqash, Abdul Rafeh
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [27] Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).
    Labriola, Matthew
    Zhu, Jason
    Gupta, Rajan
    McCall, Shannon
    Jackson, Jennifer
    White, James R.
    Weingartner, Elizabeth
    Kong, Eric
    Simone, Peter
    Papp, Eniko
    Gerding, Kelly
    Simmons, John
    George, Daniel J.
    Zhang, Tian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [28] Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).
    Labriola, Matthew
    Zhu, Jason
    Gupta, Rajan
    McCall, Shannon
    Jackson, Jennifer
    White, James R.
    Weingartner, Elizabeth
    Kong, Eric
    Simone, Peter
    Papp, Eniko
    Gerding, Kelly
    Simmons, John
    George, Daniel J.
    Zhang, Tian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [29] Predictive value of tumor mutational burden (TMB) in patients with metastatic microsatellite-stable (MSS) colorectal cancer (CRC) given first-line oxaliplatinbased chemotherapy and immune checkpoint blockade (ICB)
    Ree, Anne Hansen
    Bousquet, Paula A.
    Nilsen, Hilde L.
    Luders, Torben
    Wang, Shixiong
    Visnovska, Tina
    Bordin, Diana L.
    Hoye, Eirik
    Hamre, Hanne M.
    Kersten, Christian
    Hofsli, Eva
    Guren, Marianne G.
    Sorbye, Halfdan
    Flatmark, Kjersti
    Meltzer, Sebastian
    [J]. CANCER RESEARCH, 2024, 84 (06)
  • [30] High pretreatment neutrophil-to-lymphocyte ratio (NLR) and its reactive increase as better predictors of poor clinical outcomes compared to tumor mutation burden (TMB) in solid tumor patients treated with immune checkpoint inhibitors (ICI).
    Florou, Vaia
    Park, Wungki
    Torres, Alfredo Enrique
    Algaze, Sandra
    Saravia, Diana
    Wilky, Breelyn A.
    Merchan, Jaime R.
    Hosein, Peter Joel
    Lockhart, Albert Craig
    Lopes, Gilberto
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345